ProCE Banner Activity

Phase I/II Trial of Venetoclax/Dara/Dex (VenDd) vs Bortezomib/Dara/Dex (DVd) in t(11;14) R/R MM: Updated Analysis of MRD Negativity

Conference Coverage
Slideset

Results of the updated analysis of a phase I/II study of VenDd vs DVd showed a higher rate of MRD negativity, prolonged PFS, and trend for improved OS in patients with t(11;14) relapsed/refractory multiple myeloma.

Released: December 11, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.